Does the media refer more to IQV or CRL?

In the previous week, IQVIA and IQVIA both had 3 articles in the media. Charles River Laboratories International's average media sentiment score of 0.63 beat IQVIA's score of 0.26 indicating that Charles River Laboratories International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IQVIA 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Charles River Laboratories International 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Charles River Laboratories International (CRL) Competitors

$226.61 +1.04 (+0.46%)

Closing price 03:59 PM Eastern

Extended Trading

$226.66 +0.04 (+0.02%)

As of 07:03 PM Eastern

Compare

CRL vs. TECH, A, IQV, RVTY, and TMO

Should you buy Charles River Laboratories International stock or one of its competitors? MarketBeat compares Charles River Laboratories International with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Charles River Laboratories International include Bio-Techne (TECH), Agilent Technologies (A), IQVIA (IQV), Revvity (RVTY), and Thermo Fisher Scientific (TMO). These companies are all part of the "medical" sector.

How does Charles River Laboratories International compare to Bio-Techne?

Bio-Techne (NASDAQ:TECH) and Charles River Laboratories International (NYSE:CRL) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

In the previous week, Bio-Techne had 48 more articles in the media than Charles River Laboratories International. MarketBeat recorded 51 mentions for Bio-Techne and 3 mentions for Charles River Laboratories International. Charles River Laboratories International's average media sentiment score of 0.63 beat Bio-Techne's score of 0.52 indicating that Charles River Laboratories International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Techne	15 Very Positive mention(s)	7 Positive mention(s)	22 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Charles River Laboratories International	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bio-Techne has a net margin of 9.05% compared to Charles River Laboratories International's net margin of -4.59%. Charles River Laboratories International's return on equity of 15.36% beat Bio-Techne's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	9.05%	13.57%	10.66%
Charles River Laboratories International	-4.59%	15.36%	6.61%

Bio-Techne presently has a consensus target price of $67.79, indicating a potential downside of 4.05%. Charles River Laboratories International has a consensus target price of $211.00, indicating a potential downside of 6.89%. Given Bio-Techne's higher possible upside, equities research analysts clearly believe Bio-Techne is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.33
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69

99.0% of Bio-Techne shares are held by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are held by institutional investors. 1.3% of Bio-Techne shares are held by company insiders. Comparatively, 1.3% of Charles River Laboratories International shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Bio-Techne has higher earnings, but lower revenue than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	9.07	$73.40M	$0.69	102.39
Charles River Laboratories International	$4.02B	2.72	-$144.34M	-$3.76	N/A

Bio-Techne has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market.

Summary

Bio-Techne beats Charles River Laboratories International on 10 of the 16 factors compared between the two stocks.

How does Charles River Laboratories International compare to Agilent Technologies?

Charles River Laboratories International (NYSE:CRL) and Agilent Technologies (NYSE:A) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

Charles River Laboratories International presently has a consensus price target of $211.00, indicating a potential downside of 6.89%. Agilent Technologies has a consensus price target of $160.88, indicating a potential upside of 21.15%. Given Agilent Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Agilent Technologies is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69
Agilent Technologies	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94

In the previous week, Agilent Technologies had 16 more articles in the media than Charles River Laboratories International. MarketBeat recorded 19 mentions for Agilent Technologies and 3 mentions for Charles River Laboratories International. Charles River Laboratories International's average media sentiment score of 0.63 beat Agilent Technologies' score of 0.62 indicating that Charles River Laboratories International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agilent Technologies	6 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.9% of Charles River Laboratories International shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Agilent Technologies has a net margin of 19.55% compared to Charles River Laboratories International's net margin of -4.59%. Agilent Technologies' return on equity of 24.33% beat Charles River Laboratories International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-4.59%	15.36%	6.61%
Agilent Technologies	19.55%	24.33%	12.99%

Charles River Laboratories International has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market.

Agilent Technologies has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02B	2.72	-$144.34M	-$3.76	N/A
Agilent Technologies	$6.95B	5.40	$1.30B	$4.98	26.67

Summary

Agilent Technologies beats Charles River Laboratories International on 13 of the 17 factors compared between the two stocks.

How does Charles River Laboratories International compare to IQVIA?

IQVIA (NYSE:IQV) and Charles River Laboratories International (NYSE:CRL) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

In the previous week, IQVIA and IQVIA both had 3 articles in the media. Charles River Laboratories International's average media sentiment score of 0.63 beat IQVIA's score of 0.26 indicating that Charles River Laboratories International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IQVIA	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Charles River Laboratories International	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.6% of IQVIA shares are held by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are held by institutional investors. 1.7% of IQVIA shares are held by company insiders. Comparatively, 1.3% of Charles River Laboratories International shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

IQVIA has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market.

IQVIA presently has a consensus price target of $222.56, suggesting a potential upside of 15.00%. Charles River Laboratories International has a consensus price target of $211.00, suggesting a potential downside of 6.89%. Given IQVIA's stronger consensus rating and higher possible upside, equities research analysts plainly believe IQVIA is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69

IQVIA has a net margin of 8.33% compared to Charles River Laboratories International's net margin of -4.59%. IQVIA's return on equity of 30.50% beat Charles River Laboratories International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.33%	30.50%	6.53%
Charles River Laboratories International	-4.59%	15.36%	6.61%

IQVIA has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.31B	1.98	$1.36B	$8.07	23.98
Charles River Laboratories International	$4.02B	2.72	-$144.34M	-$3.76	N/A

Summary

IQVIA beats Charles River Laboratories International on 10 of the 15 factors compared between the two stocks.

How does Charles River Laboratories International compare to Revvity?

Revvity (NYSE:RVTY) and Charles River Laboratories International (NYSE:CRL) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

86.7% of Revvity shares are owned by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are owned by institutional investors. 0.9% of Revvity shares are owned by insiders. Comparatively, 1.3% of Charles River Laboratories International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Revvity has a net margin of 8.26% compared to Charles River Laboratories International's net margin of -4.59%. Charles River Laboratories International's return on equity of 15.36% beat Revvity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revvity	8.26%	8.00%	4.83%
Charles River Laboratories International	-4.59%	15.36%	6.61%

Revvity has higher earnings, but lower revenue than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revvity	$2.86B	4.34	$241.20M	$2.09	53.16
Charles River Laboratories International	$4.02B	2.72	-$144.34M	-$3.76	N/A

Revvity presently has a consensus target price of $108.33, suggesting a potential downside of 2.50%. Charles River Laboratories International has a consensus target price of $211.00, suggesting a potential downside of 6.89%. Given Revvity's higher possible upside, equities research analysts plainly believe Revvity is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revvity	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69

Revvity has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

In the previous week, Revvity had 12 more articles in the media than Charles River Laboratories International. MarketBeat recorded 15 mentions for Revvity and 3 mentions for Charles River Laboratories International. Charles River Laboratories International's average media sentiment score of 0.63 beat Revvity's score of -0.11 indicating that Charles River Laboratories International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revvity	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Charles River Laboratories International	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Charles River Laboratories International beats Revvity on 9 of the 16 factors compared between the two stocks.

How does Charles River Laboratories International compare to Thermo Fisher Scientific?

Charles River Laboratories International (NYSE:CRL) and Thermo Fisher Scientific (NYSE:TMO) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Thermo Fisher Scientific has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02B	2.72	-$144.34M	-$3.76	N/A
Thermo Fisher Scientific	$44.56B	4.17	$6.70B	$18.19	27.51

Charles River Laboratories International has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market. Comparatively, Thermo Fisher Scientific has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

In the previous week, Thermo Fisher Scientific had 28 more articles in the media than Charles River Laboratories International. MarketBeat recorded 31 mentions for Thermo Fisher Scientific and 3 mentions for Charles River Laboratories International. Thermo Fisher Scientific's average media sentiment score of 1.37 beat Charles River Laboratories International's score of 0.63 indicating that Thermo Fisher Scientific is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Thermo Fisher Scientific	26 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Charles River Laboratories International currently has a consensus price target of $211.00, indicating a potential downside of 6.89%. Thermo Fisher Scientific has a consensus price target of $605.09, indicating a potential upside of 20.93%. Given Thermo Fisher Scientific's stronger consensus rating and higher probable upside, analysts clearly believe Thermo Fisher Scientific is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69
Thermo Fisher Scientific	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.85

98.9% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 89.2% of Thermo Fisher Scientific shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by company insiders. Comparatively, 0.3% of Thermo Fisher Scientific shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Thermo Fisher Scientific has a net margin of 15.15% compared to Charles River Laboratories International's net margin of -4.59%. Thermo Fisher Scientific's return on equity of 16.86% beat Charles River Laboratories International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-4.59%	15.36%	6.61%
Thermo Fisher Scientific	15.15%	16.86%	8.15%

Summary

Thermo Fisher Scientific beats Charles River Laboratories International on 14 of the 17 factors compared between the two stocks.

Get Charles River Laboratories International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRL vs. The Competition

Export

Metric	Charles River Laboratories International	Medical Services Industry	Medical Sector	NYSE Exchange
Market Cap	$10.87B	$9.35B	$6.87B	$23.41B
Dividend Yield	N/A	1.66%	2.67%	4.07%
P/E Ratio	-60.27	20.21	23.31	28.95
Price / Sales	2.72	17.10	540.73	21.79
Price / Cash	10.28	114.51	48.53	25.04
Price / Book	3.52	5.95	11.01	4.80
Net Income	-$144.34M	$179.69M	$3.57B	$1.07B
7 Day Performance	21.78%	4.90%	2.56%	1.42%
1 Month Performance	25.16%	4.51%	0.89%	0.71%
1 Year Performance	49.44%	14.87%	36.84%	25.93%

Charles River Laboratories International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRL Charles River Laboratories International	1.8185 of 5 stars	$226.61 +0.5%	$211.00 -6.9%	+50.0%	$10.87B	$4.02B	N/A	19,700
TECH Bio-Techne	1.6116 of 5 stars	$55.00 -1.8%	$65.15 +18.5%	+36.8%	$8.77B	$1.22B	79.71	3,100	Analyst Downgrade
A Agilent Technologies	4.8481 of 5 stars	$124.59 -2.9%	$160.93 +29.2%	+11.6%	$36.25B	$6.95B	25.02	18,100
IQV IQVIA	3.1577 of 5 stars	$170.58 -4.8%	$222.56 +30.5%	+22.6%	$29.90B	$16.31B	21.14	93,000	Analyst Downgrade
RVTY Revvity	2.7737 of 5 stars	$97.72 -3.5%	$107.73 +10.2%	+13.6%	$11.29B	$2.86B	46.75	11,000	Analyst Revision Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CRL) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Charles River Laboratories International (CRL) Competitors

CRL vs. TECH, A, IQV, RVTY, and TMO

How does Charles River Laboratories International compare to Bio-Techne?

Summary

How does Charles River Laboratories International compare to Agilent Technologies?

Summary

How does Charles River Laboratories International compare to IQVIA?

Summary

How does Charles River Laboratories International compare to Revvity?

Summary

How does Charles River Laboratories International compare to Thermo Fisher Scientific?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRL vs. The Competition

Charles River Laboratories International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Charles River Laboratories International (CRL) Competitors

CRL vs. TECH, A, IQV, RVTY, and TMO

How does Charles River Laboratories International compare to Bio-Techne?

Does the media favor TECH or CRL?

Is TECH or CRL more profitable?

Do analysts recommend TECH or CRL?

Do institutionals & insiders believe in TECH or CRL?

Which has preferable earnings and valuation, TECH or CRL?

Which has more risk and volatility, TECH or CRL?

Summary

How does Charles River Laboratories International compare to Agilent Technologies?

Do analysts rate CRL or A?

Does the media refer more to CRL or A?

Do institutionals & insiders believe in CRL or A?

Is CRL or A more profitable?

Which has more risk & volatility, CRL or A?

Which has preferable earnings & valuation, CRL or A?

Summary

How does Charles River Laboratories International compare to IQVIA?

Does the media refer more to IQV or CRL?

Do insiders and institutionals have more ownership in IQV or CRL?

Which has more risk & volatility, IQV or CRL?

Do analysts prefer IQV or CRL?

Is IQV or CRL more profitable?

Which has stronger valuation & earnings, IQV or CRL?

Summary

How does Charles River Laboratories International compare to Revvity?

Do institutionals & insiders have more ownership in RVTY or CRL?

Is RVTY or CRL more profitable?

Which has stronger earnings & valuation, RVTY or CRL?

Do analysts rate RVTY or CRL?

Which has more volatility and risk, RVTY or CRL?

Does the media favor RVTY or CRL?

Summary

How does Charles River Laboratories International compare to Thermo Fisher Scientific?

Which has stronger valuation and earnings, CRL or TMO?

Which has more volatility & risk, CRL or TMO?

Does the media prefer CRL or TMO?

Do analysts prefer CRL or TMO?

Do institutionals & insiders believe in CRL or TMO?

Is CRL or TMO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRL vs. The Competition

Charles River Laboratories International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools